Finding better ways to personalize treatment for high-risk prostate cancer
Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer
This study is looking to help men with high-risk prostate cancer by finding special markers in their tumors that can guide doctors in choosing the best treatment for each person, so some can get stronger therapies like chemotherapy while others can skip extra side effects from long hormone treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10868607 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for high-risk prostate cancer by developing and validating biomarkers that can help tailor therapy to individual patients. By analyzing tumor samples from patients, the study aims to identify which patients would benefit from more aggressive treatments like chemotherapy, while also recognizing those who could avoid unnecessary side effects from prolonged hormone therapy. The approach involves using advanced genetic testing techniques to provide more precise treatment options based on the unique characteristics of each patient's cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with high-risk prostate cancer who are considering treatment options involving radiation therapy.
Not a fit: Patients with low-risk prostate cancer or those who have already received definitive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment plans for patients with high-risk prostate cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using biomarkers to guide treatment decisions in other cancers, suggesting potential success for this approach in prostate cancer as well.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Feng, Felix Yi-Chung — University of California, San Francisco
- Study coordinator: Feng, Felix Yi-Chung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.